Craniopharyngioma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:24:47 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Craniopharyngioma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study to evaluate the effectiveness of semaglutide for treating obesity caused by craniopharyngioma in children aged 12 to 17 years. https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-of-semaglutide-for-treating-obesity-caused-by-craniopharyngioma-in-children-aged-12-to-17-years/ Thu, 30 Apr 2026 13:08:53 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-of-semaglutide-for-treating-obesity-caused-by-craniopharyngioma-in-children-aged-12-to-17-years/ This study focuses on hypothalamic obesity, which is a type of extreme weight gain caused by damage to the hypothalamus, the part of the brain that controls hunger and energy use. This condition often occurs after a person has been treated for a craniopharyngioma, which is a rare, non-cancerous tumor located near the pituitary gland at the base of the brain. The purpose of the study is to evaluate the effectiveness of semaglutide in managing weight in children and teenagers with this condition.

Participants will be assigned to receive either semaglutide or a placebo through a subcutaneous injection, which is a medical procedure where medicine is injected into the fatty layer just under the skin. Over the course of the study, some participants will receive the medication immediately, while others may experience a delay before starting the treatment. The amount of medicine will be increased gradually over several weeks until a stable dose is reached to ensure safety and effectiveness.

]]> A study of tovorafenib for children and young adults with newly diagnosed or recurrent craniopharyngioma https://clinicaltrials.eu/trial/a-study-of-tovorafenib-for-children-and-young-adults-with-newly-diagnosed-or-recurrent-craniopharyngioma/ Wed, 29 Apr 2026 15:09:39 +0000 https://clinicaltrials.eu/trial/a-study-of-tovorafenib-for-children-and-young-adults-with-newly-diagnosed-or-recurrent-craniopharyngioma/ This study investigates the use of tovorafenib for the treatment of craniopharyngioma. This is a rare type of tumor that grows near the pituitary gland, which is a small area at the base of the brain that controls many important body functions. The study focuses on children and young adults who have either been newly diagnosed with this condition or are experiencing a recurrence, which means the tumor has returned after previous treatment.

The purpose of this study is to see how well the medication works in preventing the disease from getting worse and how it affects a person’s daily well-being. Participants will take tovorafenib in the form of either a tablet or a powder for oral suspension, which is a liquid mixture made by dissolving the medicine in water. During the course of the study, the health and daily activities of the participants will be monitored over time.

]]> A Study of Dabrafenib and Trametinib Treatment Before and After Surgery in Patients with Papillary Craniopharyngioma https://clinicaltrials.eu/trial/study-on-dabrafenib-and-trametinib-for-patients-with-papillary-craniopharyngioma/ Wed, 29 Apr 2026 14:22:56 +0000 https://clinicaltrials.eu/trial/study-on-dabrafenib-and-trametinib-for-patients-with-papillary-craniopharyngioma/ This study focuses on treating patients with papillary craniopharyngioma, which is a rare type of brain tumor that develops near the pituitary gland. The treatment involves two medications: dabrafenib and trametinib, which are targeted cancer therapies that work together to fight tumors with a specific genetic change called BRAF V600E mutation.

The purpose of this research is to determine how well these medications can shrink tumors before and after surgery. Both medications are taken by mouth – dabrafenib as capsules and trametinib as tablets. The treatment can continue for up to 12 months, during which regular brain scans using MRI (magnetic resonance imaging) will track any changes in tumor size.

During the study, doctors will monitor how the treatment affects various aspects of patients’ health, including their vision, thinking abilities, and hormone function. They will also track how long the treatment benefits last and how it impacts overall quality of life. The medications may be given either before surgery to help shrink the tumor, or after surgery to prevent the tumor from coming back.

]]>